- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770939
Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers
A Cohort Study to Evaluate the Effect of Vivostat Platelet Rich Fibrin on Diabetic Foot Ulcers.
Diabetic foot ulcers are a challenge to health care professionals because there are only few effective topical therapeutic interventions.
Growth factor treatment has shown to be beneficial for healing of diabetic foot ulcers in conjunction with extensive surgical debridement. Autologues platelet releasate which contains platelet derived growth factor appears to be more effective than standard therapy in case studies.
This protocol will evaluate the healing effect of Vivostat PRF treatment of non-eschemic foot ulcers to identify responders and to enable sample size calculation for a subsequent pivotal trial.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2400
- Woundhealing Centre Bispebjerg Hospital
-
-
-
-
-
Bad Mergentheim, Germany
- Diabetes Klinik Bad Mergentheim GmbH
-
Rheine, Germany, 48431
- Gesundheitszentrum Mathias Hospital
-
Trier, Germany
- Krankenhaus der Barmherzigen Brüder
-
-
-
-
-
Lund, Sweden
- Diabetes/ Endokrin sektion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 4 weeks history (with wound area measurements) within a wound care institution before the first visit (week -3). In case of referral the patient history must be documented
- All patients must complete a 3 week screening period i.e. they will be interviewed and accessed at the first meeting. During the 3 week period patient compliance will be monitored.
- Age >18 years
- Type I or Type II Diabetes Mellitus
- Ulcer at or below the ankle which has been present for at least 4 weeks, and has received best practice care
- Ulcer area between 0,5 and 16 cm2
- If there is more than one ulcer or bilateral ulcers, the investigator shall choose the one index ulcer to be treated (typically the largest one). The other ulcers will receive standard care and is not included in the study
- Ulcer type: University of Texas grade IA.
- Evidence of adequate arterial perfusion: Toe pressure reading of ≥ 30 mmHg or if toe is missing, transcutaneous oxygen (TcPO2) of ≥ 30mmHg on the foot.
- Patient foot is appropriately off loaded (contact cast, pneumatic walking cast)
- Orthopaedic assessment has been completed to rule out a mechanical source of ulceration
- Relative wound area reduction less than 50% from week -3 to week 0 (pre-screening period)
- Signed informed consent
Exclusion Criteria:
- Clear indication for surgery (vascular reconstruction or skin transplant)
- Ulcer with exposed bone or tendon
- Bone involvement (probe to bone or x-ray)
- Patients with 3 ulcers or more at the foot investigated
- Osteomyelitis
- Clinical signs of infections
- Necrosis in the wound (one week into the screening period).
- Patients with known MRSA
- Malnutrition. Albumin < 2,5g/dl
- Ulcers resulting from electrical, chemical, radiation burns
- HbA1c > 12%
- Male: Hb < 8 mmol/l (12,9 g/dlFemale: Hb < 7 mmol/l (11,3 g/dl)
- Platelet count <140 *109/l
- Pregnancy and fertile women not practicing sufficient birth control
- Fertile women having a positive pregnancy test week 0 Lactating women
- Patients on haemodialysis
- History of peripheral vascular repair within 4 weeks prior to study enrollment
- Bleeding disorders, haemophilia, sickle cell disease, thrombocytopenia, and leukaemia or blood dyscrasias
- Current treatment for malignancy or neoplastic disease or collagen vascular disease
- Highly communicable disease or diseases that may limit follow - up (e.g. immunocompromised conditions, hepatitis, active tuberculosis)
- Patient has inadequate venous access to draw blood
- History of alcohol or drug abuse within the last year prior to randomization
- Patient known to have psychological, developmental, physical, emotional or social dis-order or other ailments that may interfere with the study requirements
- Patients enrolled in an other clinical trial for wound treatment within 30 days prior to enrollment
- Non-compliance in the screening period
- Patients who have received growth factor therapy e.g. becaplermin within 7 days prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of completely healed ulcers after 12 weeks
Time Frame: 12 weeks
|
12 weeks
|
Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Granulation rate
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael Ruge, Vivostat
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Vivostat PRF
-
Hospital Universitario La Pazspanish society of orthopedics and traumatologyCompletedRotator Cuff Tears of the ShoulderSpain
-
Royal Brompton & Harefield NHS Foundation TrustCompletedThoracic Surgery | Air LeakUnited Kingdom
-
Shahid Beheshti University of Medical SciencesUnknownAlveolar Bone LossIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownAtrophy | Alveolar Bone LossIran, Islamic Republic of
-
Hams Hamed AbdelrahmanCompleted
-
Yuzuncu Yıl UniversityActive, not recruitingImpacted Third Molar ToothTurkey
-
Bezmialem Vakif UniversityCompletedCondition | Blood Clot | Periodontoclasia | Gingiva; Injury | Gingiva DisorderTurkey
-
Sajjad Ahmed ShakirCompleted
-
Cairo UniversityUnknown
-
University of Alabama at BirminghamNot yet recruitingBone LossUnited States